AiPD: Autoinhibited Protein Database

Q9H1Y0

Gene name	ATG5 (APG5L, ASP)
Protein name	Autophagy protein 5
Names	APG5-like, Apoptosis-specific protein
Species	Homo sapiens (Human)
KEGG Pathway	hsa:9474
EC number
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

104-175 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

104-175 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

10 structures for Q9H1Y0

Entry ID	Method	Resolution	Chain	Position	Source
4GDK	X-ray	270 A	B/E	1-275	PDB
4GDL	X-ray	288 A	B	1-275	PDB
4NAW	X-ray	220 A	B/F/J/N	1-275	PDB
4TQ0	X-ray	270 A	A/C/E	1-275	PDB
4TQ1	X-ray	180 A	A	1-275	PDB
5D7G	X-ray	300 A	A/C/E/G	1-275	PDB
5NPV	X-ray	310 A	A/C	1-275	PDB
5NPW	X-ray	310 A	A/C/E/G	1-275	PDB
7W36	X-ray	300 A	A	1-275	PDB
AF-Q9H1Y0-F1	Predicted				AlphaFoldDB

142 variants for Q9H1Y0

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
VAR_079274 CA365319959 rs1131692265 RCV000496077	122	E>D	Spinocerebellar ataxia, autosomal recessive 25 SCAR25; reduced conjugation to ATG12; decrease in autophagy activity [ClinVar, UniProt]	Yes	ClinGen ClinVar UniProt Ensembl dbSNP
TCGA novel	2	T>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3942747 rs770274468	3	D>G		No	ClinGen ExAC gnomAD
CA365321146 rs1471586990	4	D>V		No	ClinGen TOPMed
rs973267606 CA145553951	7	V>M		No	ClinGen Ensembl
TCGA novel	9	R>H	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	11	V>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA365321071 rs1562272472 COSM1132070	15	R>*	Variant assessed as Somatic; 0.0 impact. prostate [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated Ensembl NCI-TCGA
CA3942745 rs373794853	15	R>Q	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ESP ExAC NCI-TCGA TOPMed gnomAD
CA3942743 rs747253760	18	T>A		No	ClinGen ExAC gnomAD
rs780471238 CA3942742	20	F>L		No	ClinGen ExAC gnomAD
rs1333025395 CA365321030	21	T>M		No	ClinGen gnomAD
RCV000677279 CA365321031 rs1333025395	21	T>R		No	ClinGen ClinVar dbSNP gnomAD
TCGA novel	24	Q>H	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1317926026 CA365321012	24	Q>R		No	ClinGen gnomAD
CA145553949 CA365321002 rs1003280752	25	D>E		No	ClinGen TOPMed gnomAD
rs779035963 CA3942739	27	I>T		No	ClinGen ExAC gnomAD
rs756019944 CA3942738	28	T>P		No	ClinGen ExAC gnomAD
rs1314441812 CA365320956	32	A>S		No	ClinGen TOPMed
CA365320953 rs1357267494	32	A>V		No	ClinGen TOPMed
CA365320926 rs1582692575	36	Y>C		No	ClinGen Ensembl
rs775992466 CA3942722	37	L>F		No	ClinGen ExAC gnomAD
rs1450101861 CA365320864	41	R>K	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA365320827 rs1449767767	46	T>M		No	ClinGen gnomAD
rs1168222596 CA365320809	49	T>S		No	ClinGen TOPMed
VAR_036243	58	K>M	a colorectal cancer sample; somatic mutation [UniProt]	No	UniProt
rs77859116 CA3942719 RCV000949303	65	I>V		No	ClinGen ClinVar 1000Genomes ExAC TOPMed dbSNP gnomAD
rs1365555397 CA365320663	68	I>M		No	ClinGen gnomAD
rs757321575 CA3942718	70	F>L		No	ClinGen ExAC gnomAD
TCGA novel	71	E>Q	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA365320634 rs1485508522	72	Y>C		No	ClinGen TOPMed gnomAD
rs1445959690 CA365320619	74	G>D		No	ClinGen Ensembl
CA3942717 rs748058789	75	T>A		No	ClinGen ExAC TOPMed gnomAD
rs1330978852 CA365320612	75	T>I		No	ClinGen gnomAD
CA365320616 rs748058789	75	T>S		No	ClinGen ExAC TOPMed gnomAD
CA145551365 rs992870714	83	I>V		No	ClinGen TOPMed gnomAD
CA3942697 rs140900064	87	F>S		No	ClinGen ESP ExAC
CA3942696 rs768642298	91	A>S		No	ClinGen ExAC TOPMed gnomAD
CA365320184 rs1582663248	92	S>T		No	ClinGen Ensembl
CA365320168 rs1174454698	94	S>A		No	ClinGen TOPMed gnomAD
rs115576116 CA3942692	95	A>D		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA3942693 rs576645243	95	A>P		No	ClinGen 1000Genomes ExAC gnomAD
rs576645243 CA3942694	95	A>S		No	ClinGen 1000Genomes ExAC gnomAD
CA3942691 rs778666019	96	L>F		No	ClinGen ExAC gnomAD
rs1483277185 CA365320151	97	P>L		No	ClinGen gnomAD
rs959488770 CA145551364	100	I>M		No	ClinGen TOPMed gnomAD
rs1582663178 CA365320121	102	V>I		No	ClinGen Ensembl
rs756853831 CA3942690	103	H>Y		No	ClinGen ExAC TOPMed gnomAD
CA3942662 rs755637632	106	S>N		No	ClinGen ExAC gnomAD
CA365320044 rs1582646689	110	K>T		No	ClinGen Ensembl
rs1482311246 CA365320016	114	H>R		No	ClinGen gnomAD
CA145549930 rs867656702	117	S>F		No	ClinGen Ensembl
CA3942659 rs755438780	119	D>G		No	ClinGen ExAC TOPMed gnomAD
CA365319981 rs755438780	119	D>V		No	ClinGen ExAC TOPMed gnomAD
CA365319973 rs1457699582	120	A>V	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs147641218 CA3942658	121	I>V		No	ClinGen ESP ExAC TOPMed gnomAD
CA365319958 rs1199438044	123	A>T		No	ClinGen TOPMed gnomAD
CA145549928 rs1049450383	124	H>L		No	ClinGen Ensembl
TCGA novel	124	H>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3942657 rs766597836	126	M>I		No	ClinGen ExAC gnomAD
rs1404575559 CA365319927	127	S>A		No	ClinGen gnomAD
CA365319922 rs1582646600	128	C>R		No	ClinGen Ensembl
RCV000905765 rs34793250 CA3942656	129	M>V		No	ClinGen ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD
TCGA novel	138	K>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1447072698 CA365319837	139	S>N		No	ClinGen gnomAD
rs1220683182 CA365319834	139	S>R		No	ClinGen TOPMed
rs773369099 CA3942655	140	Q>H		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	141	V>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs765419687 CA3942654	141	V>I		No	ClinGen ExAC TOPMed gnomAD
CA365319801 rs1258822476	144	E>G		No	ClinGen TOPMed
TCGA novel	146	Q>H	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3942653 rs761918751	146	Q>R		No	ClinGen ExAC gnomAD
rs1221242575 CA365319777	147	K>R		No	ClinGen gnomAD
CA3942651 rs772104154	149	D>G		No	ClinGen ExAC gnomAD
rs1294150609 CA365319764	149	D>H		No	ClinGen gnomAD
TCGA novel	152	Q>*	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1364824160 CA365319742	152	Q>K		No	ClinGen gnomAD
TCGA novel	158	Q>H	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA365320494 rs376999465	167	A>S		No	ClinGen ESP ExAC TOPMed gnomAD
rs376999465 CA3942628	167	A>T		No	ClinGen ESP ExAC TOPMed gnomAD
CA365320474 rs1434229048	169	N>S		No	ClinGen gnomAD
rs1180410249 CA365320468	170	R>Q		No	ClinGen gnomAD
rs147816294 CA3942627	170	R>W		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA365320427 rs1177811286	175	Y>N		No	ClinGen TOPMed
rs1252730257 CA365320376	180	N>K		No	ClinGen TOPMed gnomAD
rs1158686992 CA365320353	183	R>C	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
CA145546460 rs867445945	183	R>H		No	ClinGen Ensembl
CA365320296 rs1234110848	189	I>M		No	ClinGen gnomAD
CA3942602 rs768319835	192	T>A		No	ClinGen ExAC gnomAD
CA365319648 rs1452647914	193	T>A		No	ClinGen gnomAD
rs746564375 CA3942601	193	T>M		No	ClinGen ExAC TOPMed gnomAD
CA365319637 rs1167250572	194	T>I		No	ClinGen TOPMed
rs779600061 CA3942600	196	R>G		No	ClinGen ExAC gnomAD
rs772578622 CA3942599	196	R>S		No	ClinGen ExAC gnomAD
rs1456721564 CA365319598	199	I>V		No	ClinGen TOPMed gnomAD
CA365319576 rs1368078005	201	K>R		No	ClinGen gnomAD
rs746306169 CA3942598	203	F>S		No	ClinGen ExAC gnomAD
rs267600752 CA145541197	204	R>C		No	ClinGen TOPMed gnomAD
rs779280595 CA3942597	204	R>H		No	ClinGen ExAC TOPMed gnomAD
CA3942596 rs757567992	205	P>S		No	ClinGen ExAC gnomAD
CA365319542 rs1284886017	206	V>M		No	ClinGen gnomAD
CA3942594 rs777898330	207	A>V		No	ClinGen ExAC
CA145541196 rs930548832	209	D>G		No	ClinGen TOPMed
rs756357015 CA3942593	209	D>N		No	ClinGen ExAC TOPMed gnomAD
CA3942591 rs373882027	213	H>D		No	ClinGen ESP ExAC TOPMed gnomAD
CA365319483 rs1246226286	213	H>R		No	ClinGen gnomAD
rs1294756448 CA365319461	216	G>R		No	ClinGen gnomAD
TCGA novel	217	D>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1209387079 CA816788699	220	K>*		No	ClinGen TOPMed
CA145541193 rs972289763	221	E>D		No	ClinGen TOPMed gnomAD
rs866038212 CA145541192	223	C>R		No	ClinGen Ensembl
rs1320893508 CA365319411	223	C>Y		No	ClinGen TOPMed gnomAD
rs761736531 CA3942587	224	P>L		No	ClinGen ExAC gnomAD
CA3942588 rs761736531	224	P>R		No	ClinGen ExAC gnomAD
rs750350218 CA3942589	224	P>S		No	ClinGen ExAC gnomAD
rs763708645 CA365319393	227	I>L		No	ClinGen ExAC TOPMed gnomAD
CA3942584 rs760314964	227	I>S		No	ClinGen ExAC gnomAD
CA365319390 rs760314964	227	I>T		No	ClinGen ExAC gnomAD
rs763708645 CA3942585	227	I>V		No	ClinGen ExAC TOPMed gnomAD
rs1475785020 CA365319383	228	D>V		No	ClinGen gnomAD
CA3942564 rs760275075	232	G>E		No	ClinGen ExAC gnomAD
CA145539485 rs898608321	233	E>G	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen Ensembl NCI-TCGA
rs1349039369 CA365319327	234	K>R		No	ClinGen gnomAD
CA3942561 rs759096052	235	K>N		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	236	N>E	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA3942560 rs773836998	236	N>K		No	ClinGen ExAC gnomAD
rs1356561310 CA365319300	238	V>L	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs1332254750 CA365319295	239	M>V		No	ClinGen gnomAD
CA365319276 rs1413986554	241	H>P		No	ClinGen gnomAD
CA145539484 rs914763225	246	M>I		No	ClinGen TOPMed gnomAD
CA365319243 rs1177100869	246	M>V		No	ClinGen TOPMed gnomAD
rs749734336 CA3942558	248	E>G		No	ClinGen ExAC gnomAD
rs1409451289 CA365319229	248	E>K		No	ClinGen gnomAD
rs773459851 CA3942557	249	T>I		No	ClinGen ExAC gnomAD
TCGA novel	250	P>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA365319215 rs1234270129	250	P>S		No	ClinGen gnomAD
CA3942556 rs770143894	251	L>V		No	ClinGen ExAC gnomAD
rs553100488 CA145539483	252	Q>*		No	ClinGen Ensembl
CA569473382 rs1460510145	253	W>*		No	ClinGen gnomAD
rs748346595 CA3942555	257	H>L		No	ClinGen ExAC gnomAD
CA145539482 rs934767863	263	N>D		No	ClinGen TOPMed gnomAD
rs757158272 CA3942550	274	T>A		No	ClinGen ExAC TOPMed gnomAD

1 associated diseases with Q9H1Y0

[MIM: 617584]: Spinocerebellar ataxia, autosomal recessive, 25 (SCAR25)

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR25 patients manifest delayed psychomotor development with delayed walking, truncal ataxia, dysmetria, and nystagmus, Cerebellar hypoplasia is seen on brain imaging. {ECO:0000269|PubMed:26812546}. Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR25 patients manifest delayed psychomotor development with delayed walking, truncal ataxia, dysmetria, and nystagmus, Cerebellar hypoplasia is seen on brain imaging. {ECO:0000269|PubMed:26812546}. Note=The disease is caused by variants affecting the gene represented in this entry.

No regional properties for Q9H1Y0

Type	Name	Position	InterPro Accession
No domain, repeats, and functional sites for Q9H1Y0

Functions

		Description
EC Number
Subcellular Localization	Cytoplasm Preautophagosomal structure membrane; Peripheral membrane protein	Colocalizes with nonmuscle actin The conjugate detaches from the membrane immediately before or after autophagosome formation is completed (By similarity) Localizes also to discrete punctae along the ciliary axoneme and to the base of the ciliary axoneme
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

11 GO annotations of cellular component

Name	Definition
Atg12-Atg5-Atg16 complex	A protein complex required for the expansion of the autophagosomal membrane. In budding yeast, this complex consists of Atg12p, Atg5p and Atg16p.
autophagosome	A double-membrane-bounded compartment that engulfs endogenous cellular material as well as invading microorganisms to target them to the lytic vacuole/lysosome for degradation as part of macroautophagy.
axon	The long process of a neuron that conducts nerve impulses, usually away from the cell body to the terminals and varicosities, which are sites of storage and release of neurotransmitter.
axoneme	The bundle of microtubules and associated proteins that forms the core of cilia (also called flagella) in eukaryotic cells and is responsible for their movements.
cytoplasm	The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol	The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
mitochondria-associated endoplasmic reticulum membrane	A zone of apposition between endoplasmic-reticulum and mitochondrial membranes, structured by bridging complexes. These contact sites are thought to facilitate inter-organelle calcium and phospholipid exchange.
phagocytic vesicle membrane	The lipid bilayer surrounding a phagocytic vesicle.
phagophore assembly site membrane	A cellular membrane associated with the phagophore assembly site.
protein-containing complex	A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together.

No GO annotations of molecular function

Name	Definition
No GO annotations for molecular function

44 GO annotations of biological process

Name	Definition
aggrephagy	Selective degradation of protein aggregates by macroautophagy.
antigen processing and presentation of endogenous antigen	The process in which an antigen-presenting cell expresses antigen (peptide or lipid) of endogenous origin on its cell surface in association with an MHC protein complex.
autophagosome assembly	The formation of a double membrane-bounded structure, the autophagosome, that occurs when a specialized membrane sac, called the isolation membrane, starts to enclose a portion of the cytoplasm.
autophagy	The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation.
autophagy of mitochondrion	The autophagic process in which mitochondria are delivered to a type of vacuole and degraded in response to changing cellular conditions.
autophagy of nucleus	A form of autophagy, by which damaged or non-essential parts of the nucleus, or even an entire nucleus is degraded.
blood vessel remodeling	The reorganization or renovation of existing blood vessels.
C-terminal protein lipidation	The covalent attachment of a lipid group to the carboxy-terminus of a protein.
cardiac muscle cell apoptotic process	A form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases, whose actions dismantle a cardiac muscle cell and result in its death. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.
cellular response to nitrogen starvation	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of nitrogen.
cellular response to nitrosative stress	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrosative stress stimulus. Nitrosative stress is a state often resulting from exposure to high levels of nitric oxide (NO) or the highly reactive oxidant peroxynitrite, which is produced following interaction of NO with superoxide anions.
chaperone-mediated autophagy	The autophagy process which begins when chaperones and co-chaperones recognize a target motif and unfold the substrate protein. The proteins are then transported to the lysosome where they are degraded.
establishment of localization in cell	Any process, occuring in a cell, that localizes a substance or cellular component. This may occur via movement, tethering or selective degradation.
heart contraction	The multicellular organismal process in which the heart decreases in volume in a characteristic way to propel blood through the body.
macroautophagy	The major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane-bounded autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane-bounded structure. Autophagosomes then fuse with a lysosome (or vacuole) releasing single-membrane-bounded autophagic bodies that are then degraded within the lysosome (or vacuole). Some types of macroautophagy, e.g. pexophagy, mitophagy, involve selective targeting of the targets to be degraded.
mucus secretion	The regulated release of mucus by the mucosa. Mucus is a viscous slimy secretion consisting of mucins and various inorganic salts dissolved in water, with suspended epithelial cells and leukocytes. The mucosa, or mucous membrane, is the membrane covered with epithelium that lines the tubular organs of the body. Mucins are carbohydrate-rich glycoproteins that have a lubricating and protective function.
negative regulation of cardiac muscle cell apoptotic process	Any process that decreases the rate or extent of cardiac cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a cardiac muscle cell and result in its death.
negative regulation of cell death	Any process that decreases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death.
negative regulation of defense response to virus	Any process that stops, prevents or reduces the rate or extent of antiviral mechanisms, thereby facilitating viral replication.
negative regulation of histone H4-K16 acetylation	Any process that stops, prevents or reduces the frequency, rate or extent of histone H4-K16 acetylation.
negative regulation of innate immune response	Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response.
negative regulation of phagocytosis	Any process that stops, prevents, or reduces the frequency, rate or extent of phagocytosis.
negative regulation of protein ubiquitination	Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of ubiquitin groups to a protein.
negative regulation of reactive oxygen species metabolic process	Any process that stops, prevents or reduces the frequency, rate or extent of reactive oxygen species metabolic process.
negative regulation of type I interferon production	Any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.
negative stranded viral RNA replication	A viral genome replication process where the template genome is negative stranded, single stranded RNA ((-)ssRNA).
negative thymic T cell selection	The process of elimination of immature T cells in the thymus which react strongly with self-antigens.
otolith development	The process whose specific outcome is the progression of the otolith over time, from its formation to the mature structure.
positive regulation of mucus secretion	Any process that activates or increases the frequency, rate or extent of the regulated release of mucus from a cell or a tissue.
positive regulation of viral translation	Any process that activates or increases the frequency, rate or extent of viral translation.
post-translational protein modification	The process of covalently altering one or more amino acids in a protein after the protein has been completely translated and released from the ribosome.
protein lipidation	The covalent attachment of lipid groups to an amino acid in a protein.
protein lipidation involved in autophagosome assembly	The protein lipidation process by which phosphatidylethanolamine is conjugated to a protein of the ATG8 family, leading to membrane insertion of the protein as a step in autophagosome assembly.
protein ubiquitination	The process in which one or more ubiquitin groups are added to a protein.
regulation of autophagosome maturation	Any process that modulates the frequency, rate or extent of autophagosome maturation.
regulation of cilium assembly	Any process that modulates the frequency, rate or extent of cilium assembly.
regulation of cytokine production involved in immune response	Any process that modulates the frequency, rate, or extent of cytokine production that contributes to an immune response.
regulation of release of sequestered calcium ion into cytosol	Any process that modulates the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.
response to fluoride	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluoride stimulus.
response to fungus	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a fungus.
response to iron(II) ion	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(II) ion stimulus.
response to xenobiotic stimulus	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical.
vasodilation	An increase in the internal diameter of blood vessels, especially arterioles or capillaries, due to relaxation of smooth muscle cells that line the vessels, and usually resulting in a decrease in blood pressure.
ventricular cardiac muscle cell development	The process whose specific outcome is the progression of a ventricular cardiac muscle cell over time, from its formation to the mature state. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. The ventricle is the part of the heart that pumps blood out of the organ.

6 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q12380	ATG5	Autophagy protein 5	Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	PR
Q3MQ24	ATG5	Autophagy protein 5	Bos taurus (Bovine)	PR
Q99J83	Atg5	Autophagy protein 5	Mus musculus (Mouse)	PR
Q3MQ04	ATG5	Autophagy protein 5	Sus scrofa (Pig)	PR
Q3MQ06	Atg5	Autophagy protein 5	Rattus norvegicus (Rat)	PR
Q9FFI2	ATG5	Autophagy protein 5	Arabidopsis thaliana (Mouse-ear cress)	PR

10	20	30	40	50	60
MTDDKDVLRD	VWFGRIPTCF	TLYQDEITER	EAEPYYLLLP	RVSYLTLVTD	KVKKHFQKVM
70	80	90	100	110	120
RQEDISEIWF	EYEGTPLKWH	YPIGLLFDLL	ASSSALPWNI	TVHFKSFPEK	DLLHCPSKDA
130	140	150	160	170	180
IEAHFMSCMK	EADALKHKSQ	VINEMQKKDH	KQLWMGLQND	RFDQFWAINR	KLMEYPAEEN
190	200	210	220	230	240
GFRYIPFRIY	QTTTERPFIQ	KLFRPVAADG	QLHTLGDLLK	EVCPSAIDPE	DGEKKNQVMI
250	260	270
HGIEPMLETP	LQWLSEHLSY	PDNFLHISII	PQPTD